A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer

被引:0
|
作者
I. Garrido-Laguna
K. A. McGregor
M. Wade
J. Weis
W. Gilcrease
L. Burr
R. Soldi
L. Jakubowski
C. Davidson
G. Morrell
J. D. Olpin
K. Boucher
D. Jones
S. Sharma
机构
[1] Huntsman Cancer Institute,Department of Internal Medicine (Division of Oncology)
[2] University of Utah,Center for Investigational Therapeutics
[3] Huntsman Cancer Institute,Department of Radiology
[4] University of Utah,Department of Biostatistics
[5] Huntsman Cancer Institute,Department of Oncological Sciences
[6] University of Utah,Department of Internal Medicine, Oncology Division
[7] Huntsman Cancer Institute,undefined
[8] University of Utah,undefined
[9] Huntsman Cancer Institute,undefined
[10] University of Utah,undefined
[11] University of Utah School of Medicine,undefined
[12] Huntsman Cancer Institute,undefined
来源
Investigational New Drugs | 2013年 / 31卷
关键词
Metastatic colorectal cancer; Epigenetics; Phase 1;
D O I
暂无
中图分类号
学科分类号
摘要
Purpose KRAS mutations are predictive of lack of response to monoclonal antibodies (mAb) against EGFR in metastatic colorectal cancer (mCRC). Most wild-type KRAS patients, however, are also resistant. Retrospective data suggest that EGFR silencing play a role in resistance to therapy. We conducted a study to evaluate the safety and efficacy of decitabine (a hypomethylating agent) in combination with panitumumab (mAb against EGFR) in mCRC patients. Experimental design 20 patients with wild-type KRAS mCRC were included in this phase I/II study. Patients were treated with decitabine at 45 mg/m2 IV over 2 h on day 1 and 15 and panitumumab 6 mg/kg IV over 1 h on day 8 and 22 every 28 days. Blood samples were collected at baseline, day 8, 15 and 22. Quantitative polymerase chain reaction was used to measure promoter-specific methylation in peripheral-blood cells (PBMCs). Results The most common adverse events were grade 1–2 (rash and hypomagnesemia); 3 (16 %) patients had grade III–IV neutropenia including one patient with neutropenic fever. Two of 20 patients (10 %) had a partial response. Both had previously received cetuximab. Ten patients had stable disease (3 of them longer than 16 weeks). Decreased methylation of the MAGE promoter was not evidenced in PBMCs. Conclusions The combination of decitabine and panitumumab was well tolerated and showed activity in wild-type KRAS mCRC patients previously treated with cetuximab. Target modulation in surrogate tissues was not achieved and tumor biopsies were not available. Future studies evaluating hypomethylating agents in combination with EGFR mAb in patients with mCRC are warranted.
引用
收藏
页码:1257 / 1264
页数:7
相关论文
共 50 条
  • [1] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    Garrido-Laguna, I.
    McGregor, K. A.
    Wade, M.
    Weis, J.
    Gilcrease, W.
    Burr, L.
    Soldi, R.
    Jakubowski, L.
    Davidson, C.
    Morrell, G.
    Olpin, J. D.
    Boucher, K.
    Jones, D.
    Sharma, S.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1257 - 1264
  • [2] Panitumumab In Metastatic Colorectal Cancer with Wild-Type KRAS
    Weber, Juliane
    McCormack, Paul L.
    BIODRUGS, 2008, 22 (06) : 403 - 411
  • [3] Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
    Strickler, John H.
    Rushing, Christel N.
    Uronis, Hope Elizabeth
    Morse, Michael
    Blobe, Gerard C.
    Zafar, Yousuf
    Hsu, Shiaowen David
    Arrowood, Christy
    Ley, Sherri Ha
    Dropkin, Evan
    Niedzwiecki, Donna
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer
    Hocking, Christopher M.
    Price, Timothy J.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2014, 7 (01) : 20 - 37
  • [5] Phase II study of combination ipilimumab, nivolumab, and panitumumab in patients with KRAS, NRAS, and BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Lee, Michael
    Loehrer, Patrick
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen
    Carlson, Cheryl
    Sanoff, Hanna
    McRee, Autumn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado, Rafael G.
    Wolf, Michael
    Peeters, Marc
    Van Cutsem, Eric
    Siena, Salvatore
    Freeman, Daniel J.
    Juan, Todd
    Sikorski, Robert
    Suggs, Sid
    Radinsky, Robert
    Patterson, Scott D.
    Chang, David D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1626 - 1634
  • [7] Candidate genes associated with primary resistance to panitumumab (Pmab) in a phase II biomarker study of patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Barry, G. S.
    Cheang, M. C.
    Leung, S.
    Zhou, C.
    Kennecke, H. F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S559 - S559
  • [8] Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Lee, Michael Sangmin
    Loehrer, Patrick J.
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen Keon
    Moore, Dominic T.
    Carlson, Cheryl Ann
    Sanoff, Hanna Kelly
    McRee, Autumn Jackson
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [9] Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study
    Chibaudel, B.
    Tournigand, C.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Nguyen, S.
    Bachet, J.
    Aissat, N.
    Blons, H.
    Laurent-Puig, P.
    De Gramont, A.
    Andre, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
    Van Cutsem, Eric
    Eng, Cathy
    Nowara, Elzbieta
    Swieboda-Sadlej, Anna
    Tebbutt, Niall C.
    Mitchell, Edith
    Davidenko, Irina
    Stephenson, Joe
    Elez, Elena
    Prenen, Hans
    Deng, Hongjie
    Tang, Rui
    McCaffery, Ian
    Oliner, Kelly S.
    Chen, Lisa
    Gansert, Jennifer
    Loh, Elwyn
    Smethurst, Dominic
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2014, 20 (16) : 4240 - 4250